DiaMedica Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.17
- Today's High:
- $3.47
- Open Price:
- $3.4
- 52W Low:
- $1.12
- 52W High:
- $3.17
- Prev. Close:
- $3.43
- Volume:
- 49668
Company Statistics
- Market Cap.:
- $70.03 million
- Book Value:
- 1.021
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -27.59%
- Return on Equity TTM:
- -45.55%
Company Profile
DiaMedica Therapeutics Inc had its IPO on 2008-01-04 under the ticker symbol DMAC.
The company operates in the Healthcare sector and Biotechnology industry. DiaMedica Therapeutics Inc has a staff strength of 16 employees.
Stock update
Shares of DiaMedica Therapeutics Inc opened at $3.4 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.17 - $3.47, and closed at $3.28.
This is a -4.37% slip from the previous day's closing price.
A total volume of 49,668 shares were traded at the close of the day’s session.
In the last one week, shares of DiaMedica Therapeutics Inc have increased by +7.19%.
DiaMedica Therapeutics Inc's Key Ratios
DiaMedica Therapeutics Inc has a market cap of $70.03 million, indicating a price to book ratio of 1.078 and a price to sales ratio of 0.
In the last 12-months DiaMedica Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-15960000. The EBITDA ratio measures DiaMedica Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, DiaMedica Therapeutics Inc’s operating margin was 0% while its return on assets stood at -27.59% with a return of equity of -45.55%.
In Q1, DiaMedica Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
DiaMedica Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.55 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into DiaMedica Therapeutics Inc’s profitability.
DiaMedica Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.1653. Its price to sales ratio in the trailing 12-months stood at 0.
DiaMedica Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $30.22 million
- Total Liabilities
- $2.81 million
- Operating Cash Flow
- $2.51 million
- Capital Expenditure
- $7000
- Dividend Payout Ratio
- 0%
DiaMedica Therapeutics Inc ended 2024 with $30.22 million in total assets and $0 in total liabilities. Its intangible assets were valued at $30.22 million while shareholder equity stood at $27.02 million.
DiaMedica Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $2.81 million in other current liabilities, in common stock, $-101449000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $2.15 million and cash and short-term investments were $28.66 million. The company’s total short-term debt was $78,000 while long-term debt stood at $0.
DiaMedica Therapeutics Inc’s total current assets stands at $29.67 million while long-term investments were $0 and short-term investments were $26.51 million. Its net receivables were $57000.00 compared to accounts payable of $1.78 million and inventory worth $0.
In 2024, DiaMedica Therapeutics Inc's operating cash flow was $2.51 million while its capital expenditure stood at $7000.
Comparatively, DiaMedica Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.28
- 52-Week High
- $3.17
- 52-Week Low
- $1.12
- Analyst Target Price
- $7.5
DiaMedica Therapeutics Inc stock is currently trading at $3.28 per share. It touched a 52-week high of $3.17 and a 52-week low of $3.17. Analysts tracking the stock have a 12-month average target price of $7.5.
Its 50-day moving average was $3.3 and 200-day moving average was $2.25 The short ratio stood at 2.52 indicating a short percent outstanding of 0%.
Around 2798.6% of the company’s stock are held by insiders while 1849.4% are held by institutions.
Frequently Asked Questions About DiaMedica Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company’s lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.